Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2019)
24 slides from Optiscan Imaging's shareholder meeting presentation, Nov 28, 2019
Slide 1: Optiscan Imaging Ltd
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 28 November 2019. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor m
Slide 3: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 4: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue Darren Lurie – Executive Chairman ▪ 470,178,800 Ordinary Shares B.LLB (Hons) and B.COM (Hons) ▪ 2,600,000 Performance Rights Former Group CFO and Head of Corporate Development for EduCo ▪ 25,600,000 unlisted options International (an investee compan
Slide 5: Optiscan's Future: Enabling "Real Time Virtual Biopsy"
Optiscan’s Future: Enabling “Real Time Virtual Biopsy” Optiscan technology changing pathology and surgical cancer practice Screening, early cancer Tumour margin detection diagnosis and targeted in cancer surgery biopsies
Slide 6: InVivage® Optiscan's Clinical System
InVivage® Optiscan’s Clinical System
Slide 7: Optiscan FIVE2 Laboratory and InVivage® Clinical Systems
Optiscan FIVE2 Laboratory and InVivage® Clinical Systems
Slide 8: Optiscan InVivage® Clinical System
Optiscan InVivage® Clinical System InVivage® Key Features • Single Hand Operation with control features operated from probe • Medical Grade Screen on Trolley Arm enabling preferred positioning by clinician • Graphic User Interface (GUI) software • DICOM compliant software to enable integration with
Slide 9: Cancer Cases Worldwide – Addressable Market
Cancer Cases Worldwide – Addressable Market 18.1M total 297,000 450,000 Oral and 570,000 2.1M Breast 3.4M Upper and Brain and Cervix & cancer cases CNS cancer Oropharyng eal cancer Uterus cancer cancer cases Lower GI cancer cases p.a. cases p.a. p.a. p.a. cases p.a. cases p.a. Carl Zeiss Flexible In
Slide 10: Oral Cancer Global Incidences
Oral Cancer Global Incidences 450,000 Cases of cancer of the Lip, 90,000 53,000 48,000 5,000 Oral Cavity and Cases in Cases in Cases in Cases Oropharynx Europe2 USA3 China4 in Au5 worldwide1 1. Global cancer statistics 2018: GLOBOCAN. https://doi.org/10.3322/caac.21492 2. American Cancer Society Est
Slide 11: Oral Cancer – Screening and Surgical Requirement
Oral Cancer – Screening and Surgical Requirement 3 to 5% of World 5% Abnormal Population Abnormal Oral Tissue 7.5 Billion Oral Tissue1 will become Cancer1 Screening and Visual Aid in Oral Early Diagnosis Cancer Surgery 1. Farah, C.S., et al., Oral Mucosal Malignancies, in Contemporary Oral Medicine:
Slide 12: Early Diagnosis: Survival Rates and Economic Cost
Early Diagnosis: Survival Rates and Economic Cost Stage 1: Per 80 – 90 % Five Patient Overall Early diagnosis Year Survival Cost for 1 Year is Rate1 $54k2 Stage 4: Per 57% Five Year Patient Overall Late diagnosis Survival Rate1 Cost for 1 Year is $133k2 “need to investigate novel techniques and “…cl
Slide 13: Oral Cancer Screening: Clinical Trials and Studies
Oral Cancer Screening: Clinical Trials and Studies Memorial Sloan Kettering Cancer Centre in New York Clinical (MSKCC) Commenced Trials & Australian Centre for Oral Oncology Research & Education Commenced - 10 patients Studies (ACOORE) in Perth imaged in the past month Melbourne Dental School (Unive
Slide 14: Australian Centre for Oral Oncology Research & Education Clinical Study
Australian Centre for Oral Oncology Research & Education Clinical Study Comparison between Optiscan imaging and histopathology Other imaging modalities for detection of oral cancer
Slide 15: New InVivage® User Interface Designed for Doctors
New InVivage® User Interface Designed for Doctors
Slide 16: Brain Cancer – Carl Zeiss Meditec AG Collaboration Update
Brain Cancer – Carl Zeiss Meditec AG Collaboration Update Date Progress April 2018 European (CE Mark) approval obtained October 2018 United States (FDA 510(k)) approval obtained May 2019 CONVIVO “Digital Biopsy Tool” (Check) an integral part of the 3 step Zeiss Tumour Workflow in Neurosurgery Novemb
Slide 17: Breast Cancer - The Most Common Cancer in Women
Breast Cancer - The Most Common Cancer in Women 2.1 ▪ 4 Stage Breast Cancer Trial at Hollywood Private Hospital (Western Australia’s largest Million new private hospital) cancer cases ▪ Nearing completion of Stage 2: 3 pathologists assisting comparison of Optiscan (globally)1 images (CLE) and H&E hi
Slide 18: Breast Cancer Trial – CLE & Histopathology Correlation
Breast Cancer Trial – CLE & Histopathology Correlation Matching CLE and H&E Cancer cells Matching CLE and H&E Cluster of cancer throughout cells (Arrows) Creation of panoramas: developing a more macro view of the specimen assisting in the CLE and H&E correlation
Slide 19: Development of new applications in research market
Development of new applications in research market Working in collaboration with CSIRO and Monash and Michigan Universities for new applications in 3D Tissue Culture and Anterior Cruciate Ligament (ACL) imaging respectively 3D tissue culture imaging application developed in collaboration with CSIRO.
Slide 20: Rapid Impact of New Distributor Strategy for Chinese Market
Rapid Impact of New Distributor Strategy for Chinese Market ▪ New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China. South and West China: Guangzhou Yunxing (Purple and Blue) East China: Under Negotiation (Green) North China: To be Advised ▪ Sal
Slide 21: Pre-clinical Marketing Collateral
Pre-clinical Marketing Collateral Pre-clinical application 3D tissue culture FIVE2 (ViewnVivo) tutorial videos for poster application developed prospective and existing users with CSIRO
Slide 22: Participation in Industry and Investor Conferences
Participation in Industry and Investor Conferences Industry Conferences Investor Conferences 2019: Light Microscopy Australia Conference at 2019: Gold Coast Investment Showcase Translational Research Institute, Brisbane 2019: 17th World Federation for Ultrasound in 2019: Australia Biotech Invest & P
Slide 23: Sloan Kettering 2019 Timeline/ Milestones
Month/Year Milestones Timeline/ February 2019 Milestones Memorial Sloan Kettering 2019 Cancer Centre (MSKCC) using Optiscan technology to develop tools for early detection, screening and intraoperative margin assessment. February 2019 Collaboration agreement with Summit Biomedical Engineering re pot
Slide 24: Summary
Summary ▪ Optiscan InVivage® Clinical System developed to enable “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection ▪ Key features of the Optiscan InVivage® Clinical System include new single hand probe controls. ▪ Pre-Submission hearing with the FDA re 510(k) cleara
Optiscan Imaging — Shareholder Meeting (November 2019) on 6ix